Nelfinavir and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Nelfinavir
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Let's talk about taking buprenorphine (a pain or opioid-dependence medicine) together with nelfinavir (an HIV medicine). Nelfinavir slows down the liver enzyme that clears buprenorphine out of your body. That means buprenorphine can build up and its effects can get stronger and last longer. The main things to watch for are too much drowsiness and slowed breathing. Both medicines can also affect your heart's rhythm (something called QT prolongation), so together that risk goes up a bit.
The good news is this is very manageable. Keep taking both as prescribed, and your care team can adjust your dose and watch you more closely so you stay safe.
Effect: Nelfinavir (potent CYP3A4 inhibitor) reduces buprenorphine clearance, increasing buprenorphine exposure (AUC/Cmax) and prolonging opioid effects. Both agents also carry additive QT-prolongation potential.
- Direction: increased buprenorphine effect (sedation, respiratory depression); buprenorphine is not a prodrug, so effect is amplified, not reduced.
- Evidence: probable; severity: major; onset unspecified.
- Management: monitor ECG/QTc; consider reducing buprenorphine dose until stable; monitor frequently for sedation and respiratory depression. On stopping nelfinavir, anticipate need to increase buprenorphine dose and watch for withdrawal. For subQ depot formulations, favor a titratable formulation when precise adjustment is needed.
What happens
An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
When buprenorphine is taken together with a CYP3A4 inhibitor, the resulting rise in buprenorphine plasma concentrations can lead to extended opioid effects, respiratory depression among them. The concurrent use of agents that alter cardiac conduction also elevates the likelihood of QT prolongation. In cases of coadministration, watch the patient carefully for any lengthening of the QT interval. It may be appropriate to lower the buprenorphine dose until steady drug effects are reached, with frequent checks for sedation and respiratory depression. Should a CYP3A4 inhibitor be stopped in someone on buprenorphine therapy, consider raising the buprenorphine dose until stable drug effects are attained, while watching for indications of opioid withdrawal2. When dose adjustment is not feasible after the CYP3A4 inhibitor is removed, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients moved from transmucosal buprenorphine used alongside CYP3A4 inhibitors, verify that the plasma buprenorphine concentration delivered by subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who need a CYP3A4 inhibitor, observe for indications of over-medication. If buprenorphine toxicity or overdose signs and symptoms appear yet the accompanying medication can be neither reduced nor stopped, lower the buprenorphine dose. When the available doses cannot deliver the intended dose, halt treatment and manage the patient using a buprenorphine formulation that enables more precise dose adjustments 1.
Why it happens (mechanism)
Additive QT interval prolongation; inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination is manageable with the right monitoring.
- Your care team may reduce your buprenorphine dose and individualize it until your response is stable.
- They may monitor you more closely for excess sedation, slowed breathing, and heart rhythm changes (an ECG may be checked).
- If the nelfinavir is later stopped, your team may need to raise the buprenorphine dose and watch for withdrawal.
- If you are on a long-acting (injectable) buprenorphine, they may consider a form that allows finer dose adjustments.
Get help right away for very slow or shallow breathing, extreme drowsiness, fainting, or palpitations. Raise any concerns with your pharmacist or prescriber.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
2 reports — tap to read
a) In a study of healthy volunteers (N=12), giving oral buprenorphine together with voriconazole produced a significant rise in the mean AUC(0 to 18 hours) of buprenorphine by 4.3-fold (from 0.43 to 2.1 nanograms (ng) x hr/mL), a 3.9-fold increase in Cmax (from 0.057 to 0.22 ng/mL), a longer half-life (from 9.1 to 14.5 hours), and greater urinary clearance (from 0.31 to 0.73 L/hr). Voriconazole likewise significantly raised exposure to the active metabolite norbuprenorphine, by nearly 4-fold for AUC(0 to 18 hours) and 3.3-fold for Cmax, while lowering its renal clearance (from 7.2 to 2.9 L/hr). Participants had mild dizziness and nausea during both phases. Subjects were given either placebo or voriconazole 400 mg twice daily on day 1, then 200 mg twice daily on days 2 to 5, followed by a 4-week washout period before switching to the alternate regimen. On the fifth day, every subject received a single oral buprenorphine dose of 0.2 mg, or 3.6 mg during the placebo phase 3.
b) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in subjects receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in studies with transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.
Common questions
Can I take Nelfinavir and Buprenorphine together?
Nelfinavir can raise buprenorphine levels and both drugs can affect heart rhythm, so watch for excess sedation, slowed breathing, and QT changes. Keep taking both as prescribed and let your care team adjust the dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Nelfinavir and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Nelfinavir and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your prescriber tells you otherwise. This combination is manageable with the right monitoring. Your care team may reduce your buprenorphine dose and individualize it until your response is stable. They may monitor you more closely for excess sedation, slowed breathing, and heart rhythm changes (an ECG may be checked). If the nelfinavir is later stopp… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Nelfinavir or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
- Fihlman M, Hemmila T, Hagelberg NM, et al: Voriconazole greatly increases the exposure to oral buprenorphine. Eur J Clin Pharmacol 2018; 74(12):1615-1622. PubMed
Keep reading about Buprenorphine
Keep reading about Nelfinavir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist